 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Merrimack Pharmaceuticals
MACK
conference date: May 8, 2018 @ 5:30 AM Pacific Time
I sold my stock after the trial failure on June 25, 2018 and will no longer cover Merrimack. No regrets, Merrimack got one therapy to market to help people, the economics just did not work out so far, but it still has some ongoing trials.
Merrimack Announces Negative Results from Pancreatic Cancer Trial [June 25, 2018]
FDA Approves Merrimack Onivyde for Pancreatic Cancer [October 22, 2015]
Analyst Conference Notes by William P. Meyers |
|||
2018 |
|||
May 8, 2018 |
|||
2017 |
|||
May 10, 2017 |
August 9, 2017 |
Nov. 8, 2017 |
March 12, 2018 |
2016 |
|||
05/02/2016 |
08/04/2016 |
11/09/2016 |
03/01/2017 |
2015 |
|||
05/07/2015 |
08/10/2015 |
11/09/2015 |
02/25/2016 |
2014 |
|||
not available |
|||
08/11/2014 |
11/10/2014 |
02/26/2015 |
|
Merrimack Phramaceuticals (MACK) is a biotechnology company focused on cancer therapies.
Merrimack Phramaceuticals web site
Merrimack Phramaceuticals investor relations page
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| INO |
| INTC |
| ISRG |
| MACK |
| MCHP |
| MYL |
| NVDA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2018 William P. Meyers